Original Article

Patient and Hospital Characteristics of Newborns with Neonatal Withdrawal Syndrome

Authors: Brook T. Alemu, PhD, MPH, Olaniyi Olayinka, MD, MPH, Beth Young, MSW, LCSW, LCAS, Dolly Pressley-Byrd, PhD, MSN, Tyler Tate, BS, Hind A. Beydoun, PhD, MPH

Abstract

Objectives: We sought to evaluate hospital resource usage patterns and determine risk factors for neonatal withdrawal syndrome (NWS) in the United States.

Methods: Using the 2016 Kids’ Inpatient Database (KID), we conducted a retrospective cross-sectional analysis of a nationally representative sample of neonates with NWS. The KID is the largest publicly available pediatric (20 years of age and younger) inpatient care database in the United States. We analyzed a stratified probability sampling of 3.1 million pediatric hospital discharges weighted to 6.3 million national discharges. Descriptive statistics for hospital and patient characteristics were identified and binary variables were analyzed using the Student t test. Multivariate regression was performed to assess the predictors of NWS. We excluded discharges if total cost or hospital length of stay (LOS) exceeded mean values by >3 standard deviations. Hospitalizations with NWS diagnosis were identified using the International Classification of Diseases, 10th Revision, Clinical Modification code P96.1 in any 1 of 30 discharge diagnostic fields.

Results: We estimated that 25,394 pediatric discharges were associated with an NWS diagnosis, totaling 403,127 inpatient days at a cost of $1.8 billion. Compared with non-NWS newborns, neonates with NWS had higher mean hospital charges ($71,540 vs $15,765), longer mean hospital stays (16 days vs 3 days), and a significantly higher proportion of low birth weight (7.2% vs 1.9%), feeding problems (19.0% vs 3.5%), respiratory diagnoses (5.6% vs 2.5%), and seizure (0.3% vs 0.1%). Among newborns with NWS, 53% were boys, 80.0% were white, 7.2% were black, 7.4% were Hispanic, and 5.3% were of other races. Hispanic neonates had the highest mean hospital charges and LOS of any other ethnic group ($123,749, 21 days). The largest proportion (83.0%) of NWS-related hospital stays were billed to Medicaid, followed by private insurance (10.3%) and self-pay (4.8%). More than one-third of NWS-related discharges (39.3%) occurred in areas with the lowest mean household annual income (≤$42,999) compared with 28.4% of neonates without NWS. Most NWS cases (53%) had ≥5 diagnoses, compared with 11% of non-NWS neonates. In the multivariate analysis, neonates with a birth weight <2500 g, feeding problems, respiratory diagnoses, seizure, >4 diagnoses, LOS >5 days, rural hospitals, Medicaid, and low-income households were significantly associated with NWS. There was a statistically significant mean hospital charge difference of $55,775 between NWS and non-NWS neonates.

Conclusions: Since 2000, the number of infants treated for NWS in the US neonatal intensive care units has increased fivefold, accounting for an estimated $1.5 billion in annual hospital expenditures. The high hospital resource usage among NWS neonates raises the possibility that care for expectant mothers who use opiates and their newborns may be able to be delivered in a more efficient and effective manner. Because the majority of the study population was covered by Medicaid programs, state policy makers should be mindful of the impact the opioid crises continue to have on expectant mothers and their infants.
Posted in: Obstetrics and Gynecology79 Pregnancy33

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hudak ML, Tan RC, et al. The Committee on Drugs. Neonatal drug withdrawal. Pediatrics 2012;129:e540-e560.
2. Berlin J, McCarver DG, Notterman DA, et al. Neonatal drug withdrawal. Pediatrics 1998;101:1079-1088.
3. Young NK, Gardner S, Otero C, et al. Substance-exposed infants: state responses to the problem. https://ncsacw.samhsa.gov/files/Substance-Exposed-Infants.pdf. Published 2009. Accessed May 29, 2020.
4. Jansson LM, Velez ML. Infants of drug-dependent mothers. Pediatr Rev 2011;32:5-12.
5. Hayes MJ, Brown MS. Epidemic of prescription opiate abuse and neonatal abstinence. JAMA 2012;307:1974-1975.
6. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998;25:139-151.
7. Whiteman VE, Salemi JL, Mogos MF, et al. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014;2014:906723.
8. Maeda A, Bateman BT, Clancy CR, et al. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 2014;121:1158-1165.
9. Casper T, Arbour MW. Identification of the pregnant woman who is using drugs: implications for perinatal and neonatal care. J Midwifery Womens Health 2013;58:697-701.
10. Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. https://store.samhsa.gov/product/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants/SMA18-5054. Published January 2018. Accessed January 18, 2019.
11. National Institute on Drug Abuse. Dramatic increases in maternal opioid use and neonatal abstinence syndrome. https://www.drugabuse.gov/related-topics/trends-statistics/infographics/dramatic-increases-in-maternal-opioid-use-neonatal-abstinence-syndrome. Published 2015. Accessed January 18, 2019.
12. Healthcare Cost and Utilization Project. KID overview. https://www.hcup-us.ahrq.gov/kidoverview.jsp. Accessed May 29, 2020.
13. O'Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics 2009;123:e614-e621.
14. Kandall SR, Albin S, Lowinson J, et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976;58:681-685.
15. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health 1991;81:1630-1635.
16. Milliren CE, Gupta M, Graham DA, et al. Hospital variation in neonatal abstinence syndrome incidence, treatment modalities, resource use, and costs across pediatric hospitals in the United States, 2013 to 2016. Hosp Pediatr 2018;8:15-20.
17. Corr TE, Hollenbeak CS. The economic burden of neonatal abstinence syndrome in the United States. Addiction 2017;112:1590-1599.
18. Filteau J, Coo H, Dow K. Trends in incidence of neonatal abstinence syndrome in Canada and associated healthcare resource utilization. Drug Alcohol Depend 2018;185:313-321.
19. Franca UL, Mustafa S, McManus ML. The growing burden of neonatal opiate exposure on children and family services in Massachusetts. Child Maltreat 2016;21:80-84.
20. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307:1934-1940.
21. Turner SD, Gomes T, Camacho X, et al. Neonatal opioid withdrawal and antenatal opioid prescribing. CMAJ Open 2015;3:E55-E61.
22. Asti L, Magers JS, Keels E, et al. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. Pediatrics 2015;135:e1494-e1500.
23. Ko JY, Wolicki S, Barfield WD, et al. CDC grand rounds: public health strategies to prevent neonatal abstinence syndrome. MMWR Morbidity Mortal Wkly Rep 2017;66:242-245.
24. Berry MA, Shah PS, Brouillette RT, et al. Predictors of mortality and length of stay for neonates admitted to children’ hospital neonatal intensive care units. J Perinatol 2008;28:297-302.
25. Nelson RE, Nelson SD, Khader K, et al. The magnitude of time-dependent bias in the estimation of excess length of stay attributable to healthcare-associated infections. Infect Control Hosp Epidemiol 2015;36:1089-1094.
26. Okoroh EM, Gee RE, Jiang B, et al. Neonatal abstinence syndrome: trend and expenditure in Louisiana Medicaid, 2003-2013. Matern Child Health J 2017;21:1479-1487.
27. Witt CE, Rudd KE, Bhatraju P, et al. Neonatal abstinence syndrome and early childhood morbidity and mortality in Washington state: a retrospective cohort study. J Perinatol 2017;37:1124-1129.
28. Burns L, Mattick RP. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev 2007;26:487-492.
29. Healthcare Cost and Utilization Project. Cost-to-charge ratio files. www.hcup-us.ahrq.gov/db/state/costtocharge.jsp. Accessed November 11, 2019.
30. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med 2016;375:2468-2479.
31. Srivastava R, Homer CJ. Length of stay for common pediatric conditions: teaching versus nonteaching hospitals. Pediatrics 2003;112:278-281.